How do I install the Endo Ascvd Risk Assessment Pooled Cohort Equations skill?

Run npx skillmds@latest add dromlakhani/endo-ascvd-risk-assessment-pooled-cohort-equations in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Ascvd Risk Assessment Pooled Cohort Equations safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: makes network calls. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Ascvd Risk Assessment Pooled Cohort Equations?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Ascvd Risk Assessment Pooled Cohort Equations free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Ascvd Risk Assessment Pooled Cohort Equations?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Ascvd Risk Assessment Pooled Cohort Equations by dromlakhani

Name: Endo Ascvd Risk Assessment Pooled Cohort Equations
Rating: 4.2 (5 reviews)
Author: dromlakhani

Endo Ascvd Risk Assessment Pooled Cohort Equations

Recommends conducting cardiovascular risk assessment by evaluating traditional risk factors and calculating 10-year atherosclerotic cardiovascular disease risk using the Pooled Cohort Equations. Use when a clinician asks about cardiovascular risk stratification in a patient with endocrine disorder.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

10-year ASCVD risk assessment using Pooled Cohort Equations

STEP 1 — Gather Information

Collect: whether the patient has established ASCVD or long-standing diabetes; if not, collect age, sex, race (white/black/other), total cholesterol, HDL-C, systolic BP, hypertension treatment (yes/no), diabetes status, smoking (yes/no); also note risk-enhancing factors (e.g., family history of premature ASCVD, Lp(a) ≥50 mg/dL).

STEP 2 — Rule In / Rule Out

If the patient has established ASCVD or long-standing diabetes, recommend statin therapy; otherwise, calculate 10-year ASCVD risk using the Pooled Cohort Equations (https://static.heart.org/riskcalc/app/index.html#!/baseline-risk).

STEP 3 — Classify or Stratify

If 10-year ASCVD risk was calculated (no ASCVD/diabetes), stratify risk: Low (<5%), Borderline (5-7.4%), Intermediate (7.5-19.9%), High (≥20%).

STEP 4 — Decide

If established ASCVD or long-standing diabetes: recommend statin therapy. Else: Assess risk-enhancing factors. If risk is Borderline (5-7.4%) or Intermediate (7.5-19.9%) and risk-enhancing factors present: Measure CAC score. If CAC=0: for Borderline, statin generally not recommended; for Intermediate, statin generally not recommended. If CAC>0: recommend statin therapy. Else: If risk <5% and no risk-enhancing factors: do not recommend statin. If risk <5% and risk-enhancing factors present: consider statin. If risk is Borderline (5-7.4%) and no risk-enhancing factors: consider statin. If risk is Intermediate (7.5-19.9%) and no risk-enhancing factors: recommend statin. If risk is High (≥20%): recommend statin therapy.

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on Pooled Cohort Equations in patients with conditions that alter risk prediction (e.g., CKD, familial hypercholesterolemia); always consider risk-enhancing factors and clinical context; avoid statin in pregnancy or active liver disease.

Concrete Clinical Example

A 55-year-old woman with type 2 diabetes and no prior ASCVD presents for risk assessment. She has no established ASCVD but has long-standing diabetes (>20 years), so per STEP 2, statin therapy is recommended.

Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, https://doi.org/10.1210/clinem/dgaa674

TODO: consider adding scripts/calc.py for the endo-ascvd-risk-assessment-pooled-cohort-equations calculator

---name: endo-ascvd-risk-assessment-pooled-cohort-equationsdescription: Recommends conducting cardiovascular risk assessment by evaluating traditional risk factors and calculating 10-year atherosclerotic cardiovascular disease risk using the Pooled Cohort Equations. Use when a clinician asks about cardiovascular risk stratification in a patient with endocrine disorder.---# 10-year ASCVD risk assessment using Pooled Cohort Equations## STEP 1 — Gather InformationCollect: whether the patient has established ASCVD or long-standing diabetes; if not, collect age, sex, race (white/black/other), total cholesterol, HDL-C, systolic BP, hypertension treatment (yes/no), diabetes status, smoking (yes/no); also note risk-enhancing factors (e.g., family history of premature ASCVD, Lp(a) ≥50 mg/dL).## STEP 2 — Rule In / Rule OutIf the patient has established ASCVD or long-standing diabetes, recommend statin therapy; otherwise, calculate 10-year ASCVD risk using the Pooled Cohort Equations (https://static.heart.org/riskcalc/app/index.html#!/baseline-risk).## STEP 3 — Classify or StratifyIf 10-year ASCVD risk was calculated (no ASCVD/diabetes), stratify risk: Low (<5%), Borderline (5-7.4%), Intermediate (7.5-19.9%), High (≥20%).## STEP 4 — DecideIf established ASCVD or long-standing diabetes: recommend statin therapy.Else: Assess risk-enhancing factors. If risk is Borderline (5-7.4%) or Intermediate (7.5-19.9%) and risk-enhancing factors present: Measure CAC score. If CAC=0: for Borderline, statin generally not recommended; for Intermediate, statin generally not recommended. If CAC>0: recommend statin therapy. Else: If risk <5% and no risk-enhancing factors: do not recommend statin. If risk <5% and risk-enhancing factors present: consider statin. If risk is Borderline (5-7.4%) and no risk-enhancing factors: consider statin. If risk is Intermediate (7.5-19.9%) and no risk-enhancing factors: recommend statin. If risk is High (≥20%): recommend statin therapy.## Clinical Guardrails / Mimics / PitfallsDo not rely solely on Pooled Cohort Equations in patients with conditions that alter risk prediction (e.g., CKD, familial hypercholesterolemia); always consider risk-enhancing factors and clinical context; avoid statin in pregnancy or active liver disease.## Concrete Clinical ExampleA 55-year-old woman with type 2 diabetes and no prior ASCVD presents for risk assessment. She has no established ASCVD but has long-standing diabetes (>20 years), so per STEP 2, statin therapy is recommended.**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, https://doi.org/10.1210/clinem/dgaa674> **TODO:** consider adding scripts/calc.py for the endo-ascvd-risk-assessment-pooled-cohort-equations calculator

Frequently asked questions